글로벌 Onychomycosis 약물 시장 - 업계 동향 및 2028년까지의 예측

Onychomycosis 약물 시장의 시장 분석 및 통찰력

Data Bridge Market Research는 2021-2028년 예측 기간 동안 onychomycosis 약물이 약 5.94%의 CAGR을 보일 것이라고 분석했습니다. 많은 연구 기관과 제약 회사에 기금을 제공하기 위한 정부 정책과 이니셔티브의 증가, onychomycosis의 유병률 증가, 연구 개발 활동에 대한 지출 증가가 onychomycosis 약물 시장 성장에 기여하는 주요 요인입니다.

티네아 엉귀움(tinea unguium)이라고도 알려진 오니코미코시스는 손톱과 발톱에 발생하는 진균 감염입니다. 오니코미코시스는 변형, 불편함, 통증으로 이어질 수 있으며 심각한 문제를 일으킬 수 있습니다. 이 질병의 주요 증상은 흰색 또는 노란색 손톱 변색과 같은 손톱 모양의 변화입니다.

치료에 대한 인식이 높아지고, onychomycosis의 유병률이 높아지는 것은 onychomycosis 약물 시장의 성장을 촉진하는 주요 요인입니다. 의료 인프라 개발에 대한 지출이 증가하고, 노인 인구가 계속 증가하고, 개인의 가처분 소득이 증가하는 것도 시장 성장을 촉진하고 있습니다. 또한, 생명공학 및 제약 회사의 신약 및 치료법 개발을 위한 연구 개발 활동이 증가함에 따라 이 시장에 수익성 있는 시장 성장 기회가 창출될 것입니다.

그러나 여러 회사의 특허 만료는 onychomycosis 약물 시장 성장에 큰 도전이 될 것입니다. 연구 개발 능력에 대한 높은 자본 요구 사항은 시장 성장률을 더욱 탈선시킬 것입니다. 또한 일부 중산층 및 저소득 국가에서 onychomycosis에 대한 인식 부족은 시장 성장률에 더욱 도전이 될 것입니다.   

This onychomycosis drug market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on onychomycosis drug market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Onychomycosis Drug Market Scope and Market Size

The onychomycosis drug market is segmented on the basis of types, drugs, treatment, route of administration, distribution channel and end users. The growth amongst these segments will help you analyse meagre growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.

• Based on types, the onychomycosis drug market is segmented into proximal subungual, distal subungual, candidal, white superficial and total dystrophic.
• On the basis of drugs, the onychomycosis drug market is segmented into griseofulvin, ketoconazole, ciclopirox, terbinafine and others.
• On the basis of treatment, the onychomycosis drug market is segmented into medication, topical treatment and debridement.
• On the basis of route of administration, the onychomycosis drug market is segmented into oral, topical and others.
• On the basis of distribution channel, the onychomycosis drug market is segmented into direct, online pharmacy, retailers and others.
• On the basis of end users, the onychomycosis drug market is segmented into hospitals, homecare, specialty clinics and others.

Global Onychomycosis Drug Market Country Level Analysis

Global onychomycosis drug market is analysed and market size insights and trends are provided by country, types, drugs, treatment, route of administration, distribution channel and end users as referenced above.

The countries covered in the onychomycosis drug market report are the U.S., Canada and Mexico in North America, Peru, Brazil, Argentina and Rest of South America as part of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific (APAC) in Asia-Pacific (APAC), South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA).

North America dominates the onychomycosis drug market owing to the prevalence of advanced healthcare infrastructure and rising prevalence of onychomycosis. Asia-Pacific is projected to score highest growth rate and exhibit the highest CAGR for the forecast period. This is because of the rising expenditure to develop healthcare infrastructure coupled with rising awareness about onychomycosis.   

The country section of the onychomycosis drug market report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as consumption volumes, production sites and volumes, import export analysis, price trend analysis, cost of raw materials, down-stream and upstream value chain analysis are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Patient Epidemiology Analysis

The onychomycosis drug market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to onychomycosis drug market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the onychomycosis drug market in the growth period.

Competitive Landscape and Onychomycosis Drug Market Share Analysis

The onychomycosis drug market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies’ focus related to onychomycosis drug market.

onychomycosis 약물 시장 보고서에서 다루는 주요 업체는 Bayer AG, F. Hoffmann-La Roche Ltd, Novartis AG, Astrazeneca, Pfizer Inc., Sanofi, Johnson & Johnson Services, Inc., AbbVie Inc., Allergan, Merck & Co., Inc., Amgen Inc., Teva Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, GlaxoSmithKline plc, Lupin Pharmaceuticals, Inc., Eli Lilly and Company, Bristol-Myers Squibb Company, Bausch Health Companies Inc., GALDERMA 및 Moberg Pharma AB 등 국내 및 글로벌 업체입니다. 시장 점유율 데이터는 글로벌, 북미, 유럽, 아시아 태평양(APAC), 중동 및 아프리카(MEA) 및 남미에 대해 개별적으로 제공됩니다. DBMR 분석가는 경쟁 우위를 이해하고 각 경쟁자에 대한 경쟁 분석을 개별적으로 제공합니다.

SKU-45051